Key Takeaways
- Bristol Myers Squibb (BMS) will present at J.P. Morgan’s 43rd Annual Healthcare Conference on January 13, 2025.
- A fireside chat and live webcast will feature insights on BMS’s strategies and innovations.
- Replay and presentation materials will be available post-event.
Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, has announced its participation in J.P. Morgan’s 43rd Annual Healthcare Conference. The presentation, scheduled for Monday, January 13, 2025, at 7:30 a.m. PT/10:30 a.m. ET, will feature a fireside chat discussing the company’s strategic direction and commitment to innovation. This highly anticipated event underscores BMS’s role in shaping the future of healthcare and advancing therapies for serious diseases.
The event will be streamed live via webcast on BMS’s investor website, allowing stakeholders to engage with the company’s insights and vision in real-time. Additionally, presentation materials will be made available at the start of the webcast to enhance viewer experience and understanding. Following the event, a replay and archived version of the presentation will remain accessible, ensuring that interested parties can revisit the session at their convenience.
About Bristol Myers Squibb
Bristol Myers Squibb is dedicated to transforming lives through science by discovering, developing, and delivering innovative medicines. The company’s robust pipeline of therapies addresses some of the world’s most pressing healthcare challenges, reinforcing its position as a leader in the biopharmaceutical industry.
Guided by a mission to help patients prevail over serious diseases, BMS combines cutting-edge research with a steadfast commitment to improving health outcomes worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
